SK chemicals Site ManagerSK chemicals Conducts Marketing Education on Futhan!
On the 1st anniversary of the release of Futhan, a blood thinner
- Lectures by Marketing/Training Specialists from Torii, Japan - Re-affirmed Futhan＇s 10 times more effective inhibition of protease. - Resolved to achieve 10 billion won/year in sales by 2007 |
The Life Science Division of SK chemicalss (CEO Kim Chang-geun) conducts marketing education on February 2 and 3.
The current education classes were organized to commemorate the 1st anniversary of the launch of Futhan injection (a nafamostat mesilate-based blood thinner) by its Japanese developer,Torii, last year. The classes were conducted in person by marketing and training specialists from the Japanese company.
The classes began with introductory remarks by Miyazaki, the assistant manager of the Torii Development Team, on the first day and progressed with an introduction to the “Strategy to Expand the Futhan Market in Japan” by Tsukiyama, the Futhan Project’s deputy manager, and talks on “Futhan and Drug Interaction” by Okuyama, assistant manager, and the “Japanese PMS System” by Matumoto, manager, in that order.
During the lectures interpreted by Cheon Se-yeong, SK chemicalss’ Development Team Leader, the audience fielded sincere questions and answers for all the lecture topics, prolonging the schedule and leaving the lecturers in a sweat.
In particular, Tsukiyama, who has worked as Futhan project manager for 20 years, gave easily comprehensible and accurate answers to the questions in a composed manner. He was praised by the audience as “a true project manager with an outstanding artisan spirit gleaned from 20 years of project management experience”.
SK chemicals obtained a local government permit to sell Futhan in Korea on 1 June 2004. Futhan is used to prevent blood coagulation during hemodialysis. It is also an effective cure for acute pancreatitis and DIC (Dichlorodiphenyltrichloroethane).
Heparin, so far used to inhibit blood coagulation, has too long a half life (90 minutes) and carries a risk of bleeding symptoms and other abnormalities by impeding the overall blood coagulation function of the body and during hemodialysis before or after a surgical operation.
Furthermore, it caused inconveniences and risks to patients as blood is coagulated within the hemodialyzer even when no blood thinner is being used.
Futhan, however, prevents coagulation by inhibiting protease such as trombin extensively and powerfully. It also extends the curing opportunity to patients who require hemodialysis despite serious risks of bleeding, since its half life is very short (5 to 8 minutes).
Torii, the developer of Futhan, is a pharmaceutical company with over 840 employees in Japan and an 84-year tradition of concentrating its R&D resources to develop treatment for immune inflammation, the central nervous system, the metabolism, and cardiovascular disorders